Breakthrough COVID-19 is mild in vaccinated patients with hematological malignancy receiving tixagevimab-cilgavimab as pre-exposure prophylaxis. V G Hall, C Lim, N R Saunders, E Klimevski, T H O Nguyen, L Kedzierski, J F Seymour, V Wadhwa, K A Thursky,M K Yong, K Kedzierska,M A Slavin,B W TehLeukemia & lymphoma（2023）引用 0|浏览3暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
